Dr. Buse, as an endocrinologist with a specialty in diabetes, I'm hoping you can help educate both myself and my psychiatrist readers about diabetes and antipsychotics. To begin with, we've been hearing a lot lately about the "metabolic syndrome." What is it?

Raymond Cavanaugh, M.D., is a psychiatrist in private practice in Lawrence and Lynn, Massachusetts, and has an interesting take on the differences between the atypicals.

We have some good news and we have some bad news. First, the good news: Cymbalta (generic name: duloxetine) is an effective dual reuptake antidepressant with a good safety profile. Now, the bad news: it appears to have no advantages over existing antidepressants.

Whether you do ECT (electroconvulsive therapy) or not, and research indicates that less than 8% of you actually perform it (Hermann et al, Am J Psychiatry 1998; 155:889-894), you need to know about it, because you will have to decide when to refer your treatment-resistant patients for it, and you will have to know what to say to them about it as they pepper you with a multitude of questions, as they always do (and should).

Sorry, no earthshaking developments in the antidepressant world in 2003, but here are some developments that you’ll find useful in your practice.

Dr. O'Reardon, you had mentioned at the end of our last interview (see TCR, Vol. 1, No. 1) some of the augmentation and combination strategies that you like to use in your clinic but we didn't have time to get into the actual specifics of these. To begin with, how do you decide when to augment? What kinds of drug failures do you try to establish?

The first ECT (electroconvulsive therapy), was performed by an Italian psychiatrist, Ugo Cerletti, who had initially assessed the safety of the treatment with dogs. He performed the first treatment on a human on April 18, 1938.

In case you haven't noticed, antidepressants are under attack. Articles such as "The Emperor's New Drugs" and popular books like "Prozac Backlash" point to a growing public sentiment that psychiatrists need to shed a little hubris.

Throughout every issue of The Carlat Report, you, poor reader, have been subjected to citations of multiple research studies, and to terms such as "controlled," "open-label", "statistically significant." In this article, TCR dives head-first into research methodology, with the aim of helping you to become smarter consumers of statistical trickery.

Index to Volume 1, 2003 of The Carlat Report